Spruce Biosciences, Inc. announced completion of target enrollment of 72 patients and closure of screening in the CAHmelia-203 clinical trial evaluating tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH) and provided updated anticipated milestones. As a result, The company anticipates that final enrollment will exceed the original target of 72 patients, and project topline results from this study along with the topline results from all cohorts in CAHptain clinical trial in pediatric classic CAH in the first quarter of 2024. The company anticipates that final enrollment will exceed its original target of 72 patients, the company's original target of 72 patients.

The company expects that final enrollment will exceed the initial target of 72 patients, and projects topline results from this trial along with the top line results from all cohorts in the Phase 2b clinical trial in adult classic CAH patients on supraraphysiologic doses of glucocorticoid dosing. The company has updated its anticipated upcoming milestones as follows: Completition of enrollment in the SHYSHYCAHmelia-204 clinical trial in adults with classic CAH and highly elevated levels of A4 in early first quarter of 2024. Topline results from all cohorts in the phase 2 CAHptain clinical trialin pediatric classic CAH patients in the first quarter of 2024; Topline results from the CAHmelia- 203 clinical trial in adult classicCAH patients on supraphysiologic doses of glucoseocorticoids with normal or near normal levels of A4 in the third quarter of 2024.